{"transactions":[{"id":692823,"issuer":{"id":4564,"kind":"organization","name":"Braveheart Bio, Inc."},"owners":[{"id":25356,"kind":"person","name":"Lubner David Charles","position":1,"cik":"0001572000","reported_name":"Lubner David Charles","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-08-07T20:30:35.000Z","date":"2026-08-05","kind":"grant","planned":false,"acquired":true,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/36th of the shares subject to such option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of July 23, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date."}],"balance_after":60000,"derivative":{"exercise_price":18,"expiration_date":"2036-08-04","underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0001470831-26-000796","document":"wk-form4_1786134631.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1572000/000147083126000796/wk-form4_1786134631.xml","form_type":"4"}},{"id":692822,"issuer":{"id":4564,"kind":"organization","name":"Braveheart Bio, Inc."},"owners":[{"id":25356,"kind":"person","name":"Lubner David Charles","position":1,"cik":"0001572000","reported_name":"Lubner David Charles","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-08-07T20:30:35.000Z","date":"2026-08-07","kind":"purchase","planned":false,"acquired":true,"shares":55555,"price":18,"value":999990.0,"ownership":{"direct":true},"balance_after":55555,"source":{"system":"sec-edgar","filing":"0001470831-26-000796","document":"wk-form4_1786134631.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1572000/000147083126000796/wk-form4_1786134631.xml","form_type":"4"}},{"id":744761,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":25356,"kind":"person","name":"Lubner David Charles","position":1,"cik":"0001572000","reported_name":"Lubner David Charles","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2026-06-09T21:13:55.000Z","date":"2026-06-05","kind":"grant","planned":false,"acquired":true,"shares":35152,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 5, 2026. The shares underlying the option are scheduled to vest in full on the earlier of (i) June 5, 2027 or (ii) the date of the Issuer's 2027 Annual Meeting of Stockholders, subject to continued service."}],"balance_after":35152,"derivative":{"exercise_price":17.04,"expiration_date":"2036-06-04","underlying":"Common Stock","underlying_shares":35152},"source":{"system":"sec-edgar","filing":"0001193125-26-264025","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000119312526264025/ownership.xml","form_type":"4"}},{"id":751230,"issuer":{"id":5255,"kind":"organization","name":"CRESCENT BIOPHARMA, INC.","symbol":"CBIO"},"owners":[{"id":25356,"kind":"person","name":"Lubner David Charles","position":1,"cik":"0001572000","reported_name":"Lubner David Charles","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-03T23:48:11.000Z","date":"2026-06-02","kind":"grant","planned":false,"acquired":true,"shares":11050,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase 11,050 of the Issuer's ordinary shares and vests in full on the earlier of (i) June 2, 2027 or (ii) the date of the Issuer's next annual meeting of shareholders, in each case, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":11050,"derivative":{"exercise_price":17.01,"expiration_date":"2036-06-02","underlying":"Ordinary Shares","underlying_shares":11050},"source":{"system":"sec-edgar","filing":"0001628280-26-040582","document":"wk-form4_1780530489.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1253689/000162828026040582/wk-form4_1780530489.xml","form_type":"4"}},{"id":798895,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":25356,"kind":"person","name":"Lubner David Charles","position":1,"cik":"0001572000","reported_name":"Lubner David Charles","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-28T20:56:31.000Z","date":"2026-04-24","kind":"gift","planned":false,"acquired":false,"shares":53625,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"source":{"system":"sec-edgar","filing":"0001193125-26-187601","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000119312526187601/ownership.xml","form_type":"4"}},{"id":798630,"issuer":{"id":15294,"kind":"organization","name":"Arcellx, Inc.","symbol":"ACLX"},"owners":[{"id":25356,"kind":"person","name":"Lubner David Charles","position":1,"cik":"0001572000","reported_name":"Lubner David Charles","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-04-28T20:28:18.000Z","date":"2026-04-28","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":9174,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, each outstanding option to purchase shares of Common Stock (a \"Company Option\"), whether or not vested, and which had a per share exercise price that was less than the Closing Amount, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Closing Amount over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger, and (ii) one (1) CVR for each share subject to such Company Option immediately prior to the effective time of the Merger."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, each outstanding option to purchase shares of Common Stock (a \"Company Option\"), whether or not vested, and which had a per share exercise price that was less than the Closing Amount, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Closing Amount over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger, and (ii) one (1) CVR for each share subject to such Company Option immediately prior to the effective time of the Merger."}],"balance_after":0,"derivative":{"exercise_price":63.68,"expiration_date":"2035-05-29","underlying":"Common Stock","underlying_shares":9174},"source":{"system":"sec-edgar","filing":"0001572000-26-000002","document":"form4-04282026_080414.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1572000/000157200026000002/form4-04282026_080414.xml","form_type":"4"}},{"id":798629,"issuer":{"id":15294,"kind":"organization","name":"Arcellx, Inc.","symbol":"ACLX"},"owners":[{"id":25356,"kind":"person","name":"Lubner David Charles","position":1,"cik":"0001572000","reported_name":"Lubner David Charles","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-04-28T20:28:18.000Z","date":"2026-04-28","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":8011,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, each outstanding option to purchase shares of Common Stock (a \"Company Option\"), whether or not vested, and which had a per share exercise price that was less than the Closing Amount, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Closing Amount over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger, and (ii) one (1) CVR for each share subject to such Company Option immediately prior to the effective time of the Merger."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, each outstanding option to purchase shares of Common Stock (a \"Company Option\"), whether or not vested, and which had a per share exercise price that was less than the Closing Amount, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Closing Amount over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger, and (ii) one (1) CVR for each share subject to such Company Option immediately prior to the effective time of the Merger."}],"balance_after":0,"derivative":{"exercise_price":51.3,"expiration_date":"2034-05-28","underlying":"Common Stock","underlying_shares":8011},"source":{"system":"sec-edgar","filing":"0001572000-26-000002","document":"form4-04282026_080414.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1572000/000157200026000002/form4-04282026_080414.xml","form_type":"4"}},{"id":798628,"issuer":{"id":15294,"kind":"organization","name":"Arcellx, Inc.","symbol":"ACLX"},"owners":[{"id":25356,"kind":"person","name":"Lubner David Charles","position":1,"cik":"0001572000","reported_name":"Lubner David Charles","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-04-28T20:28:18.000Z","date":"2026-04-28","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":11459,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, each outstanding option to purchase shares of Common Stock (a \"Company Option\"), whether or not vested, and which had a per share exercise price that was less than the Closing Amount, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Closing Amount over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger, and (ii) one (1) CVR for each share subject to such Company Option immediately prior to the effective time of the Merger."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, each outstanding option to purchase shares of Common Stock (a \"Company Option\"), whether or not vested, and which had a per share exercise price that was less than the Closing Amount, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Closing Amount over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger, and (ii) one (1) CVR for each share subject to such Company Option immediately prior to the effective time of the Merger."}],"balance_after":0,"derivative":{"exercise_price":37.94,"expiration_date":"2033-06-14","underlying":"Common Stock","underlying_shares":11459},"source":{"system":"sec-edgar","filing":"0001572000-26-000002","document":"form4-04282026_080414.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1572000/000157200026000002/form4-04282026_080414.xml","form_type":"4"}},{"id":798627,"issuer":{"id":15294,"kind":"organization","name":"Arcellx, Inc.","symbol":"ACLX"},"owners":[{"id":25356,"kind":"person","name":"Lubner David Charles","position":1,"cik":"0001572000","reported_name":"Lubner David Charles","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-04-28T20:28:18.000Z","date":"2026-04-28","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":61538,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, each outstanding option to purchase shares of Common Stock (a \"Company Option\"), whether or not vested, and which had a per share exercise price that was less than the Closing Amount, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Closing Amount over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger, and (ii) one (1) CVR for each share subject to such Company Option immediately prior to the effective time of the Merger."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, each outstanding option to purchase shares of Common Stock (a \"Company Option\"), whether or not vested, and which had a per share exercise price that was less than the Closing Amount, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Closing Amount over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger, and (ii) one (1) CVR for each share subject to such Company Option immediately prior to the effective time of the Merger."}],"balance_after":0,"derivative":{"exercise_price":15,"expiration_date":"2032-02-03","underlying":"Common Stock","underlying_shares":61538},"source":{"system":"sec-edgar","filing":"0001572000-26-000002","document":"form4-04282026_080414.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1572000/000157200026000002/form4-04282026_080414.xml","form_type":"4"}},{"id":798626,"issuer":{"id":15294,"kind":"organization","name":"Arcellx, Inc.","symbol":"ACLX"},"owners":[{"id":25356,"kind":"person","name":"Lubner David Charles","position":1,"cik":"0001572000","reported_name":"Lubner David Charles","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-04-28T20:28:18.000Z","date":"2026-04-28","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":31794,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, each outstanding option to purchase shares of Common Stock (a \"Company Option\"), whether or not vested, and which had a per share exercise price that was less than the Closing Amount, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Closing Amount over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger, and (ii) one (1) CVR for each share subject to such Company Option immediately prior to the effective time of the Merger."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, each outstanding option to purchase shares of Common Stock (a \"Company Option\"), whether or not vested, and which had a per share exercise price that was less than the Closing Amount, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Closing Amount over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger, and (ii) one (1) CVR for each share subject to such Company Option immediately prior to the effective time of the Merger."}],"balance_after":0,"derivative":{"exercise_price":6.66,"expiration_date":"2031-12-07","underlying":"Common Stock","underlying_shares":31794},"source":{"system":"sec-edgar","filing":"0001572000-26-000002","document":"form4-04282026_080414.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1572000/000157200026000002/form4-04282026_080414.xml","form_type":"4"}},{"id":798625,"issuer":{"id":15294,"kind":"organization","name":"Arcellx, Inc.","symbol":"ACLX"},"owners":[{"id":25356,"kind":"person","name":"Lubner David Charles","position":1,"cik":"0001572000","reported_name":"Lubner David Charles","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-04-28T20:28:18.000Z","date":"2026-04-28","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":59405,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, each outstanding option to purchase shares of Common Stock (a \"Company Option\"), whether or not vested, and which had a per share exercise price that was less than the Closing Amount, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Closing Amount over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger, and (ii) one (1) CVR for each share subject to such Company Option immediately prior to the effective time of the Merger."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, each outstanding option to purchase shares of Common Stock (a \"Company Option\"), whether or not vested, and which had a per share exercise price that was less than the Closing Amount, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Closing Amount over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger, and (ii) one (1) CVR for each share subject to such Company Option immediately prior to the effective time of the Merger."}],"balance_after":0,"derivative":{"exercise_price":6.28,"expiration_date":"2031-06-09","underlying":"Common Stock","underlying_shares":59405},"source":{"system":"sec-edgar","filing":"0001572000-26-000002","document":"form4-04282026_080414.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1572000/000157200026000002/form4-04282026_080414.xml","form_type":"4"}},{"id":798624,"issuer":{"id":15294,"kind":"organization","name":"Arcellx, Inc.","symbol":"ACLX"},"owners":[{"id":25356,"kind":"person","name":"Lubner David Charles","position":1,"cik":"0001572000","reported_name":"Lubner David Charles","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-04-28T20:28:18.000Z","date":"2026-04-28","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":13626,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, each outstanding option to purchase shares of Common Stock (a \"Company Option\"), whether or not vested, and which had a per share exercise price that was less than the Closing Amount, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Closing Amount over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger, and (ii) one (1) CVR for each share subject to such Company Option immediately prior to the effective time of the Merger."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, each outstanding option to purchase shares of Common Stock (a \"Company Option\"), whether or not vested, and which had a per share exercise price that was less than the Closing Amount, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Closing Amount over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger, and (ii) one (1) CVR for each share subject to such Company Option immediately prior to the effective time of the Merger."}],"balance_after":0,"derivative":{"exercise_price":6.83,"expiration_date":"2030-08-31","underlying":"Common Stock","underlying_shares":13626},"source":{"system":"sec-edgar","filing":"0001572000-26-000002","document":"form4-04282026_080414.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1572000/000157200026000002/form4-04282026_080414.xml","form_type":"4"}},{"id":798623,"issuer":{"id":15294,"kind":"organization","name":"Arcellx, Inc.","symbol":"ACLX"},"owners":[{"id":25356,"kind":"person","name":"Lubner David Charles","position":1,"cik":"0001572000","reported_name":"Lubner David Charles","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-28T20:28:18.000Z","date":"2026-04-28","kind":"other","planned":false,"acquired":false,"shares":21659,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated February 22, 2026 (the \"Merger Agreement\"), by and among Arcellx, Inc. (\"Company\"), Gilead Sciences, Inc. (\"Parent\"), and Ravens Sub, Inc., a wholly owned subsidiary of Parent (\"Purchaser\"), the shares of common stock of Company that were tendered to Purchaser prior to the expiration time of the offer were exchanged for (x) $115.00 per share (\"Closing Amount\"), net to the seller in cash, without interest, subject to withholding tax, plus (y) one contractual contingent value right (a \"CVR\"), which represents the right to receive one contingent payment of $5.00 per CVR in cash, without interest, and subject to any withholding tax, pursuant to the terms and subject to the conditions of a contingent value rights agreement. After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into Company (the \"Merger\"), with Company surviving the Merger as a wholly owned subsidiary of Parent."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001572000-26-000002","document":"form4-04282026_080414.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1572000/000157200026000002/form4-04282026_080414.xml","form_type":"4"}},{"id":935035,"issuer":{"id":15294,"kind":"organization","name":"Arcellx, Inc.","symbol":"ACLX"},"owners":[{"id":25356,"kind":"person","name":"Lubner David Charles","position":1,"cik":"0001572000","reported_name":"Lubner David Charles","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-01-21T00:59:40.000Z","date":"2026-01-20","kind":"exercise","planned":true,"acquired":false,"shares":6000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Shares issued pursuant to the Issuer's 2017 Equity Incentive Plan (the \"2017 Plan\"). Subject to the Reporting Person continuing to be a Service Provider (as defined 2017 Plan) through each applicable date, one forty-eighth (1/48th) of the shares subject to the option shall vest each month following the Vesting Commencement Date on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). \"Vesting Commencement Date\" shall mean June 9, 2021."}],"balance_after":59405,"derivative":{"exercise_price":6.28,"expiration_date":"2031-06-09","underlying":"Common Stock","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001193125-26-017002","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1572000/000119312526017002/ownership.xml","form_type":"4"}},{"id":935034,"issuer":{"id":15294,"kind":"organization","name":"Arcellx, Inc.","symbol":"ACLX"},"owners":[{"id":25356,"kind":"person","name":"Lubner David Charles","position":1,"cik":"0001572000","reported_name":"Lubner David Charles","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-01-21T00:59:40.000Z","date":"2026-01-20","kind":"sale","planned":true,"acquired":false,"shares":6000,"price":75,"value":450000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale of shares reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person on September 29, 2025."}],"balance_after":21659,"source":{"system":"sec-edgar","filing":"0001193125-26-017002","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1572000/000119312526017002/ownership.xml","form_type":"4"}},{"id":935033,"issuer":{"id":15294,"kind":"organization","name":"Arcellx, Inc.","symbol":"ACLX"},"owners":[{"id":25356,"kind":"person","name":"Lubner David Charles","position":1,"cik":"0001572000","reported_name":"Lubner David Charles","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-01-21T00:59:40.000Z","date":"2026-01-20","kind":"exercise","planned":true,"acquired":true,"shares":6000,"price":6.28,"value":37680.0,"ownership":{"direct":true},"balance_after":27659,"source":{"system":"sec-edgar","filing":"0001193125-26-017002","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1572000/000119312526017002/ownership.xml","form_type":"4"}},{"id":1061286,"issuer":{"id":76319,"kind":"organization","name":"CARGO Therapeutics, Inc.","symbol":"CRGX"},"owners":[{"id":25356,"kind":"person","name":"Lubner David Charles","position":1,"cik":"0001572000","reported_name":"Lubner David Charles","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2025-08-19T20:43:51.000Z","date":"2025-08-19","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":25000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Disposed of pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of July 7, 2025, by and among CARGO Therapeutics, Inc. (the \"Issuer\"), Concentra Biosciences, LLC (\"Parent\") and Concentra Merger Sub VII, Inc., a wholly owned subsidiary of Parent (\"Merger Sub\"). On August 18, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a \"Share\") for an offer price of (i) $4.379 per Share in cash (the \"Cash Amount\"), and (ii) one non-transferable contractual contingent value right (each, a \"CVR\"), subject to and in accordance with the terms of the Contingent Value Rights Agreement (the \"CVR Agreement\"), in each case, without interest, and subject to any applicable withholding taxes (the Cash Amount plus one CVR, collectively, the \"Offer Price\"). [continues to Footnote 2]"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"[continues from Footnote 1] Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the \"Merger\"). As of immediately prior to and conditioned upon the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an \"Option\") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was canceled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger [continues to Footnote 3]"},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"[continues from Footnote 2] and (b) one CVR in respect of each Share underlying such Option; provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount that was then outstanding it was canceled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Disposed of pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of July 7, 2025, by and among CARGO Therapeutics, Inc. (the \"Issuer\"), Concentra Biosciences, LLC (\"Parent\") and Concentra Merger Sub VII, Inc., a wholly owned subsidiary of Parent (\"Merger Sub\"). On August 18, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a \"Share\") for an offer price of (i) $4.379 per Share in cash (the \"Cash Amount\"), and (ii) one non-transferable contractual contingent value right (each, a \"CVR\"), subject to and in accordance with the terms of the Contingent Value Rights Agreement (the \"CVR Agreement\"), in each case, without interest, and subject to any applicable withholding taxes (the Cash Amount plus one CVR, collectively, the \"Offer Price\"). [continues to Footnote 2]"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"[continues from Footnote 1] Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the \"Merger\"). As of immediately prior to and conditioned upon the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an \"Option\") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was canceled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger [continues to Footnote 3]"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"[continues from Footnote 2] and (b) one CVR in respect of each Share underlying such Option; provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount that was then outstanding it was canceled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":4.35,"expiration_date":"2035-06-17","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001610717-25-000303","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1572000/000161071725000303/form4.xml","form_type":"4"}},{"id":1103557,"issuer":{"id":5255,"kind":"organization","name":"CRESCENT BIOPHARMA, INC.","symbol":"CBIO"},"owners":[{"id":25356,"kind":"person","name":"Lubner David Charles","position":1,"cik":"0001572000","reported_name":"Lubner David Charles","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-23T22:41:28.000Z","date":"2025-06-23","kind":"grant","planned":false,"acquired":true,"shares":9023,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase shares of the Issuer's ordinary shares and vests in full on the earlier of (i) June 23, 2026 or (ii) the date of the Issuer's next annual meeting of shareholders, in each case, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":9023,"derivative":{"exercise_price":15.3,"expiration_date":"2035-06-23","underlying":"Ordinary Shares","underlying_shares":9023},"source":{"system":"sec-edgar","filing":"0001104659-25-061816","document":"tm2518376-13_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1253689/000110465925061816/tm2518376-13_4seq1.xml","form_type":"4"}},{"id":1104638,"issuer":{"id":76319,"kind":"organization","name":"CARGO Therapeutics, Inc.","symbol":"CRGX"},"owners":[{"id":25356,"kind":"person","name":"Lubner David Charles","position":1,"cik":"0001572000","reported_name":"Lubner David Charles","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-20T21:40:12.000Z","date":"2025-06-18","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares subject to the option shall vest on the earlier of (i) the one year anniversary of June 18, 2025 or (ii) the next Annual Meeting following June 18, 2025, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":25000,"derivative":{"exercise_price":4.35,"expiration_date":"2035-06-17","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001610717-25-000245","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1572000/000161071725000245/form4.xml","form_type":"4"}},{"id":1125257,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":25356,"kind":"person","name":"Lubner David Charles","position":1,"cik":"0001572000","reported_name":"Lubner David Charles","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2025-06-04T01:40:35.000Z","date":"2025-05-30","kind":"grant","planned":false,"acquired":true,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on May 30, 2025. The shares underlying the option are scheduled to vest in full on the earlier of (i) May 30, 2026 or (ii) the date of the Issuer's 2026 Annual Meeting of Stockholders, subject to continued service."}],"balance_after":35000,"derivative":{"exercise_price":11.96,"expiration_date":"2035-05-29","underlying":"Common Stock","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0000950170-25-081358","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017025081358/ownership.xml","form_type":"4"}},{"id":1128914,"issuer":{"id":15294,"kind":"organization","name":"Arcellx, Inc.","symbol":"ACLX"},"owners":[{"id":25356,"kind":"person","name":"Lubner David Charles","position":1,"cik":"0001572000","reported_name":"Lubner David Charles","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-05-30T20:11:25.000Z","date":"2025-05-29","kind":"grant","planned":false,"acquired":true,"shares":9174,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to the reporting person's continuing to be a Service Provider (as defined in the 2022 Equity Incentive Plan) through such applicable vesting date, one hundred percent (100%) of the shares subject to the award will vest on the earlier to occur of May 29, 2026 or the next annual meeting of stockholders."}],"balance_after":9174,"derivative":{"exercise_price":63.68,"expiration_date":"2035-05-29","underlying":"Common Stock","underlying_shares":9174},"source":{"system":"sec-edgar","filing":"0001415889-25-014980","document":"form4-05302025_080509.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1572000/000141588925014980/form4-05302025_080509.xml","form_type":"4"}},{"id":1135496,"issuer":{"id":4763,"kind":"organization","name":"Vor Biopharma Inc.","symbol":"VOR"},"owners":[{"id":25356,"kind":"person","name":"Lubner David Charles","position":1,"cik":"0001572000","reported_name":"Lubner David Charles","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-05-23T21:45:12.000Z","date":"2025-05-22","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted to the Reporting Person pursuant to the Issuer's non-employee director compensation policy. The shares underlying the option vest and become exercisable on the earlier of (i) May 22, 2026 or (ii) the Issuer's next annual meeting of stockholders following the grant date, in each case, subject to the Reporting Person's continued service as a director through such date."}],"balance_after":30000,"derivative":{"exercise_price":0.1868,"expiration_date":"2035-05-21","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001415889-25-014529","document":"form4-05232025_050508.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817229/000141588925014529/form4-05232025_050508.xml","form_type":"4"}},{"id":1488071,"issuer":{"id":76319,"kind":"organization","name":"CARGO Therapeutics, Inc.","symbol":"CRGX"},"owners":[{"id":25356,"kind":"person","name":"Lubner David Charles","position":1,"cik":"0001572000","reported_name":"Lubner David Charles","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-06T20:29:21.000Z","date":"2024-06-04","kind":"grant","planned":false,"acquired":true,"shares":23742,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares subject to the option shall vest on the earlier of (i) one year anniversary of June 4, 2024 (the \"Vesting Commencement Date\") or (ii) the next Annual Meeting following June 4, 2024, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":23742,"derivative":{"exercise_price":19.17,"expiration_date":"2034-06-03","underlying":"Common Stock","underlying_shares":23742},"source":{"system":"sec-edgar","filing":"0001610717-24-000300","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1572000/000161071724000300/form4.xml","form_type":"4"}},{"id":1488070,"issuer":{"id":15294,"kind":"organization","name":"Arcellx, Inc.","symbol":"ACLX"},"owners":[{"id":25356,"kind":"person","name":"Lubner David Charles","position":1,"cik":"0001572000","reported_name":"Lubner David Charles","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-06-06T20:15:47.000Z","date":"2024-05-28","kind":"grant","planned":false,"acquired":true,"shares":8011,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to the reporting person's continuing to be a Service Provider (as defined in the 2022 Equity Incentive Plan) through such applicable vesting date, one hundred percent (100%) of the shares subject to the award will vest on the earlier to occur of May 28, 2025 or the next annual meeting of stockholders."}],"balance_after":8011,"derivative":{"exercise_price":51.3,"expiration_date":"2034-05-28","underlying":"Common Stock","underlying_shares":8011},"source":{"system":"sec-edgar","filing":"0001415889-24-015741","document":"form4-06062024_080643.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1572000/000141588924015741/form4-06062024_080643.xml","form_type":"4"}},{"id":1500561,"issuer":{"id":4763,"kind":"organization","name":"Vor Biopharma Inc.","symbol":"VOR"},"owners":[{"id":25356,"kind":"person","name":"Lubner David Charles","position":1,"cik":"0001572000","reported_name":"Lubner David Charles","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-05-28T20:10:18.000Z","date":"2024-05-23","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted to the Reporting Person pursuant to the Issuer's non-employee director compensation policy. The shares underlying the option vest and become exercisable on the earlier of (i) May 23, 2025 or (ii) the Issuer's next annual meeting of stockholders following the grant date, in each case, subject\nto the Reporting Person's continued service as a director through such date."}],"balance_after":30000,"derivative":{"exercise_price":1.61,"expiration_date":"2034-05-22","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001415889-24-014648","document":"form4-05282024_040514.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817229/000141588924014648/form4-05282024_040514.xml","form_type":"4"}},{"id":1502164,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":25356,"kind":"person","name":"Lubner David Charles","position":1,"cik":"0001572000","reported_name":"Lubner David Charles","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2024-05-24T21:10:09.000Z","date":"2024-05-22","kind":"grant","planned":false,"acquired":true,"shares":25133,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on May 22, 2024. The shares underlying the option are scheduled to vest in full on the earlier of (i) May 22, 2025 or (ii) the date of the Issuer's 2025 Annual Meeting of Stockholders, subject to continued service."}],"balance_after":25133,"derivative":{"exercise_price":31.53,"expiration_date":"2034-05-21","underlying":"Common Stock","underlying_shares":25133},"source":{"system":"sec-edgar","filing":"0000950170-24-064724","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024064724/ownership.xml","form_type":"4"}},{"id":1699341,"issuer":{"id":95793,"kind":"organization","name":"POINT Biopharma Global Inc.","symbol":"PNT"},"owners":[{"id":25356,"kind":"person","name":"Lubner David Charles","position":1,"cik":"0001572000","reported_name":"Lubner David Charles","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-12-27T22:37:18.000Z","date":"2023-12-27","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":44749,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash, without interest, less any applicable tax withholding, equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash, without interest, less any applicable tax withholding, equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash, without interest, less any applicable tax withholding, equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable."}],"balance_after":0,"derivative":{"exercise_price":9.12,"expiration_date":"2029-06-01","underlying":"Common Stock","underlying_shares":44749},"source":{"system":"sec-edgar","filing":"0001104659-23-129769","document":"tm2333785-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1572000/000110465923129769/tm2333785-3_4seq1.xml","form_type":"4"}},{"id":1699340,"issuer":{"id":95793,"kind":"organization","name":"POINT Biopharma Global Inc.","symbol":"PNT"},"owners":[{"id":25356,"kind":"person","name":"Lubner David Charles","position":1,"cik":"0001572000","reported_name":"Lubner David Charles","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-12-27T22:37:18.000Z","date":"2023-12-27","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":25614,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash, without interest, less any applicable tax withholding, equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash, without interest, less any applicable tax withholding, equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash, without interest, less any applicable tax withholding, equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable."}],"balance_after":0,"derivative":{"exercise_price":8.31,"expiration_date":"2028-06-02","underlying":"Common Stock","underlying_shares":25614},"source":{"system":"sec-edgar","filing":"0001104659-23-129769","document":"tm2333785-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1572000/000110465923129769/tm2333785-3_4seq1.xml","form_type":"4"}},{"id":1699339,"issuer":{"id":95793,"kind":"organization","name":"POINT Biopharma Global Inc.","symbol":"PNT"},"owners":[{"id":25356,"kind":"person","name":"Lubner David Charles","position":1,"cik":"0001572000","reported_name":"Lubner David Charles","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-12-27T22:37:18.000Z","date":"2023-12-27","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":25000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash, without interest, less any applicable tax withholding, equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash, without interest, less any applicable tax withholding, equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash, without interest, less any applicable tax withholding, equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable."}],"balance_after":0,"derivative":{"exercise_price":8.47,"expiration_date":"2027-07-06","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001104659-23-129769","document":"tm2333785-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1572000/000110465923129769/tm2333785-3_4seq1.xml","form_type":"4"}},{"id":1699338,"issuer":{"id":95793,"kind":"organization","name":"POINT Biopharma Global Inc.","symbol":"PNT"},"owners":[{"id":25356,"kind":"person","name":"Lubner David Charles","position":1,"cik":"0001572000","reported_name":"Lubner David Charles","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-12-27T22:37:18.000Z","date":"2023-12-27","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":3600,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of October 2, 2023, by and among POINT Biopharma Global Inc. (the \"Issuer\"), Eli Lilly and Company (the \"Parent\"), and Yosemite Falls Acquisition Corporation, a wholly owned subsidiary of Parent (\"Merger Sub\"), pursuant to which Merger Sub completed a cash tender offer for shares of common stock of the Issuer (each, a \"Share\"). After completion of the cash tender offer, Merger Sub merged with and into the Issuer (the \"Merger\"), effective as of December 27, 2023 (the \"Effective Time\"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $12.50 in cash (the \"Merger Consideration\"), without interest and less any applicable tax withholding."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of October 2, 2023, by and among POINT Biopharma Global Inc. (the \"Issuer\"), Eli Lilly and Company (the \"Parent\"), and Yosemite Falls Acquisition Corporation, a wholly owned subsidiary of Parent (\"Merger Sub\"), pursuant to which Merger Sub completed a cash tender offer for shares of common stock of the Issuer (each, a \"Share\"). After completion of the cash tender offer, Merger Sub merged with and into the Issuer (the \"Merger\"), effective as of December 27, 2023 (the \"Effective Time\"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $12.50 in cash (the \"Merger Consideration\"), without interest and less any applicable tax withholding."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-23-129769","document":"tm2333785-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1572000/000110465923129769/tm2333785-3_4seq1.xml","form_type":"4"}},{"id":1699337,"issuer":{"id":95793,"kind":"organization","name":"POINT Biopharma Global Inc.","symbol":"PNT"},"owners":[{"id":25356,"kind":"person","name":"Lubner David Charles","position":1,"cik":"0001572000","reported_name":"Lubner David Charles","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-12-27T22:37:18.000Z","date":"2023-12-26","kind":"other","planned":false,"acquired":false,"shares":35400,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of October 2, 2023, by and among POINT Biopharma Global Inc. (the \"Issuer\"), Eli Lilly and Company (the \"Parent\"), and Yosemite Falls Acquisition Corporation, a wholly owned subsidiary of Parent (\"Merger Sub\"), pursuant to which Merger Sub completed a cash tender offer for shares of common stock of the Issuer (each, a \"Share\"). After completion of the cash tender offer, Merger Sub merged with and into the Issuer (the \"Merger\"), effective as of December 27, 2023 (the \"Effective Time\"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $12.50 in cash (the \"Merger Consideration\"), without interest and less any applicable tax withholding."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of October 2, 2023, by and among POINT Biopharma Global Inc. (the \"Issuer\"), Eli Lilly and Company (the \"Parent\"), and Yosemite Falls Acquisition Corporation, a wholly owned subsidiary of Parent (\"Merger Sub\"), pursuant to which Merger Sub completed a cash tender offer for shares of common stock of the Issuer (each, a \"Share\"). After completion of the cash tender offer, Merger Sub merged with and into the Issuer (the \"Merger\"), effective as of December 27, 2023 (the \"Effective Time\"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $12.50 in cash (the \"Merger Consideration\"), without interest and less any applicable tax withholding."}],"balance_after":3600,"source":{"system":"sec-edgar","filing":"0001104659-23-129769","document":"tm2333785-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1572000/000110465923129769/tm2333785-3_4seq1.xml","form_type":"4"}},{"id":1743408,"issuer":{"id":76319,"kind":"organization","name":"CARGO Therapeutics, Inc.","symbol":"CRGX"},"owners":[{"id":25356,"kind":"person","name":"Lubner David Charles","position":1,"cik":"0001572000","reported_name":"Lubner David Charles","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2023-11-13T23:49:17.000Z","date":"2023-11-09","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/36th of the shares subject to the option vest on each monthly anniversary measured from November 10, 2023 (the \"Vesting Commencement Date\"), such that 100% of the shares subject to the option will be fully vested and exercisable on the third anniversary of the Vesting Commencement Date."}],"balance_after":25000,"derivative":{"exercise_price":15,"expiration_date":"2033-11-08","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001610717-23-000348","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1572000/000161071723000348/form4.xml","form_type":"4"}},{"id":1851449,"issuer":{"id":15294,"kind":"organization","name":"Arcellx, Inc.","symbol":"ACLX"},"owners":[{"id":25356,"kind":"person","name":"Lubner David Charles","position":1,"cik":"0001572000","reported_name":"Lubner David Charles","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-16T20:17:27.000Z","date":"2023-06-14","kind":"grant","planned":false,"acquired":true,"shares":11459,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to the reporting person's continuing to be a Service Provider (as defined in the 2022 Equity Incentive Plan) through such applicable vesting date, one hundred percent (100%) of the shares subject to the award will vest on the earlier to occur of June 14, 2024 or the next annual meeting of stockholders."}],"balance_after":11459,"derivative":{"exercise_price":37.94,"expiration_date":"2033-06-14","underlying":"Common Stock","underlying_shares":11459},"source":{"system":"sec-edgar","filing":"0001209191-23-037830","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1572000/000120919123037830/doc4.xml","form_type":"4"}},{"id":1866181,"issuer":{"id":95793,"kind":"organization","name":"POINT Biopharma Global Inc.","symbol":"PNT"},"owners":[{"id":25356,"kind":"person","name":"Lubner David Charles","position":1,"cik":"0001572000","reported_name":"Lubner David Charles","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-05T21:35:31.000Z","date":"2023-06-01","kind":"grant","planned":false,"acquired":true,"shares":44749,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest 100% on the first anniversary of the grant date."}],"balance_after":44749,"derivative":{"exercise_price":9.12,"expiration_date":"2029-06-01","underlying":"Common Stock","underlying_shares":44749},"source":{"system":"sec-edgar","filing":"0001104659-23-068141","document":"tm2317857-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1572000/000110465923068141/tm2317857-1_4seq1.xml","form_type":"4"}},{"id":1870201,"issuer":{"id":4763,"kind":"organization","name":"Vor Biopharma Inc.","symbol":"VOR"},"owners":[{"id":25356,"kind":"person","name":"Lubner David Charles","position":1,"cik":"0001572000","reported_name":"Lubner David Charles","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-02T20:36:39.000Z","date":"2023-05-26","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted to the Reporting Person pursuant to the Issuer's non-employee director compensation policy. The shares underlying the option vest and become exercisable on the earlier of (i) May 26, 2024 or (ii) the Issuer's next annual meeting of stockholders following the grant date, in each case, subject to the Reporting Person's continued service as a director through such date."}],"balance_after":30000,"derivative":{"exercise_price":4.79,"expiration_date":"2033-05-25","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001209191-23-033810","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817229/000120919123033810/doc4.xml","form_type":"4"}},{"id":1878266,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":25356,"kind":"person","name":"Lubner David Charles","position":1,"cik":"0001572000","reported_name":"Lubner David Charles","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-05-25T22:37:59.000Z","date":"2023-05-24","kind":"grant","planned":false,"acquired":true,"shares":24900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on May 24, 2023. The shares underlying the option are scheduled to vest in full on the earlier of (i) May 24, 2024 or (ii) the date of the Issuer's 2024 Annual Meeting of Stockholders."}],"balance_after":24900,"derivative":{"exercise_price":13.49,"expiration_date":"2033-05-23","underlying":"Common Stock","underlying_shares":24900},"source":{"system":"sec-edgar","filing":"0001209191-23-032278","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000120919123032278/doc4.xml","form_type":"4"}},{"id":2103168,"issuer":{"id":95793,"kind":"organization","name":"POINT Biopharma Global Inc.","symbol":"PNT"},"owners":[{"id":25356,"kind":"person","name":"Lubner David Charles","position":1,"cik":"0001572000","reported_name":"Lubner David Charles","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-11-28T21:03:22.000Z","date":"2022-11-23","kind":"purchase","acquired":true,"shares":3600,"price":6.85,"value":24660.0,"ownership":{"direct":true},"balance_after":3600,"source":{"system":"sec-edgar","filing":"0001104659-22-122395","document":"tm2231459-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1572000/000110465922122395/tm2231459-2_4seq1.xml","form_type":"4"}},{"id":2212179,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":25356,"kind":"person","name":"Lubner David Charles","position":1,"cik":"0001572000","reported_name":"Lubner David Charles","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-07-06T22:21:21.000Z","date":"2022-07-05","kind":"grant","acquired":true,"shares":7222,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted on July 31, 2020, with 100% of the option to vest upon the clearance date of an Investigational New Drug (IND) application submitted to the U.S. Food and Drug Administration (FDA) by the Company with respect to one of its product candidates. On July 5, 2022, in connection with the clearance by the FDA of the Company's IND application for DYNE-251, the Compensation Committee determined that the performance condition had been achieved."}],"balance_after":7222,"derivative":{"exercise_price":5.54,"expiration_date":"2030-07-30","underlying":"Common Stock","underlying_shares":7222},"source":{"system":"sec-edgar","filing":"0001209191-22-041337","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000120919122041337/doc4.xml","form_type":"4"}},{"id":2230132,"issuer":{"id":4763,"kind":"organization","name":"Vor Biopharma Inc.","symbol":"VOR"},"owners":[{"id":25356,"kind":"person","name":"Lubner David Charles","position":1,"cik":"0001572000","reported_name":"Lubner David Charles","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-16T21:05:39.000Z","date":"2022-06-14","kind":"grant","acquired":true,"shares":16911,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted to the Reporting Person pursuant to the Issuer's non-employee director compensation policy. The shares underlying the option vest and become exercisable on the earlier of (i) June 14, 2023 or (ii) the Issuer's next annual meeting of stockholders following the grant date, in each case, subject to the Reporting Person's continued service as a director through such date."}],"balance_after":16911,"derivative":{"exercise_price":4.26,"expiration_date":"2032-06-13","underlying":"Common Stock","underlying_shares":16911},"source":{"system":"sec-edgar","filing":"0001209191-22-037501","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817229/000120919122037501/doc4.xml","form_type":"4"}},{"id":2242574,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":25356,"kind":"person","name":"Lubner David Charles","position":1,"cik":"0001572000","reported_name":"Lubner David Charles","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-06T20:07:59.000Z","date":"2022-06-03","kind":"grant","acquired":true,"shares":19596,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 3, 2022. The shares underlying the option are scheduled to vest in full on the earlier of (i) June 3, 2023 or (ii) the date of the Issuer's 2023 Annual Meeting of Stockholders."}],"balance_after":19596,"derivative":{"exercise_price":4.58,"expiration_date":"2032-06-02","underlying":"Common Stock","underlying_shares":19596},"source":{"system":"sec-edgar","filing":"0001209191-22-034495","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000120919122034495/doc4.xml","form_type":"4"}},{"id":2241272,"issuer":{"id":95793,"kind":"organization","name":"POINT Biopharma Global Inc.","symbol":"PNT"},"owners":[{"id":25356,"kind":"person","name":"Lubner David Charles","position":1,"cik":"0001572000","reported_name":"Lubner David Charles","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-06T20:04:35.000Z","date":"2022-06-02","kind":"grant","acquired":true,"shares":25614,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest 100% on the first anniversary of the grant date."}],"balance_after":25614,"derivative":{"exercise_price":8.31,"expiration_date":"2028-06-02","underlying":"Common Stock","underlying_shares":25614},"source":{"system":"sec-edgar","filing":"0001104659-22-068509","document":"tm2217697-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1572000/000110465922068509/tm2217697-3_4seq1.xml","form_type":"4"}},{"id":2342181,"issuer":{"id":2273,"kind":"organization","name":"Disc Medicine, Inc.","symbol":"IRON"},"owners":[{"id":25356,"kind":"person","name":"Lubner David Charles","position":1,"cik":"0001572000","reported_name":"Lubner David Charles","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-03-09T23:15:52.000Z","date":"2021-03-12","kind":"grant","acquired":true,"shares":17529,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest and become exercisable in 36 equal monthly installments following the Grant Date, provided that as of each such date the Grantee remains in a business relationship with the Company."}],"balance_after":17529,"derivative":{"exercise_price":17,"expiration_date":"2031-03-11","underlying":"Common Stock","underlying_shares":17529},"source":{"system":"sec-edgar","filing":"0001209191-22-017671","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1816736/000120919122017671/doc4a.xml","form_type":"4/A","original_submission_date":"2021-03-15"}},{"id":2342179,"issuer":{"id":2273,"kind":"organization","name":"Disc Medicine, Inc.","symbol":"IRON"},"owners":[{"id":25356,"kind":"person","name":"Lubner David Charles","position":1,"cik":"0001572000","reported_name":"Lubner David Charles","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-03-09T23:13:07.000Z","date":"2021-10-04","kind":"grant","acquired":true,"shares":0,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"This Form 4/A amends and restates the original Form 4 filed on October 6, 2021 (\"Original Form 4\").  The stock option reported on the Original Form 4 was reported in error and was never granted to the Reporting Person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This Form 4/A amends and restates the original Form 4 filed on October 6, 2021 (\"Original Form 4\").  The stock option reported on the Original Form 4 was reported in error and was never granted to the Reporting Person."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"This Form 4/A amends and restates the original Form 4 filed on October 6, 2021 (\"Original Form 4\").  The stock option reported on the Original Form 4 was reported in error and was never granted to the Reporting Person."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":0},"source":{"system":"sec-edgar","filing":"0001209191-22-017668","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1816736/000120919122017668/doc4a.xml","form_type":"4/A","original_submission_date":"2021-10-06"}},{"id":2405927,"issuer":{"id":15294,"kind":"organization","name":"Arcellx, Inc.","symbol":"ACLX"},"owners":[{"id":25356,"kind":"person","name":"Lubner David Charles","position":1,"cik":"0001572000","reported_name":"Lubner David Charles","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series C Preferred Stock","published_at":"2022-02-09T22:52:55.000Z","date":"2022-02-08","kind":"exercise","acquired":false,"shares":21659,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series C Preferred Stock, par value $0.001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.001 per share (\"Common Stock\") immediately prior to the closing of the Issuer's initial public offering of its Common Stock.  The right to convert the Series C Preferred Stock into Common Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series C Preferred Stock, par value $0.001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.001 per share (\"Common Stock\") immediately prior to the closing of the Issuer's initial public offering of its Common Stock.  The right to convert the Series C Preferred Stock into Common Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series C Preferred Stock, par value $0.001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.001 per share (\"Common Stock\") immediately prior to the closing of the Issuer's initial public offering of its Common Stock.  The right to convert the Series C Preferred Stock into Common Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series C Preferred Stock, par value $0.001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.001 per share (\"Common Stock\") immediately prior to the closing of the Issuer's initial public offering of its Common Stock.  The right to convert the Series C Preferred Stock into Common Stock had no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":21659},"source":{"system":"sec-edgar","filing":"0001209191-22-008159","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1572000/000120919122008159/doc4.xml","form_type":"4"}},{"id":2405926,"issuer":{"id":15294,"kind":"organization","name":"Arcellx, Inc.","symbol":"ACLX"},"owners":[{"id":25356,"kind":"person","name":"Lubner David Charles","position":1,"cik":"0001572000","reported_name":"Lubner David Charles","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-02-09T22:52:55.000Z","date":"2022-02-08","kind":"exercise","acquired":true,"shares":21659,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series C Preferred Stock, par value $0.001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.001 per share (\"Common Stock\") immediately prior to the closing of the Issuer's initial public offering of its Common Stock.  The right to convert the Series C Preferred Stock into Common Stock had no expiration date."}],"balance_after":21659,"source":{"system":"sec-edgar","filing":"0001209191-22-008159","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1572000/000120919122008159/doc4.xml","form_type":"4"}},{"id":2409834,"issuer":{"id":15294,"kind":"organization","name":"Arcellx, Inc.","symbol":"ACLX"},"owners":[{"id":25356,"kind":"person","name":"Lubner David Charles","position":1,"cik":"0001572000","reported_name":"Lubner David Charles","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-02-07T23:00:35.000Z","date":"2022-02-03","kind":"grant","acquired":true,"shares":61538,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2022 Equity Incentive Plan) through each applicable vesting date, one-third (1/3rd) of the shares subject to the option will vest each year following Equity Grant Date on the same day of the month as the Equity Grant Date (or, if there is no corresponding day in a particular month, then the last day of the month) over three (3) years.  \"Equity Grant Date\" shall mean February 3, 2022."}],"balance_after":61538,"derivative":{"exercise_price":15,"expiration_date":"2032-02-03","underlying":"Common Stock","underlying_shares":61538},"source":{"system":"sec-edgar","filing":"0001209191-22-007567","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1572000/000120919122007567/doc4.xml","form_type":"4"}},{"id":2547290,"issuer":{"id":2273,"kind":"organization","name":"Disc Medicine, Inc.","symbol":"IRON"},"owners":[{"id":25356,"kind":"person","name":"Lubner David Charles","position":1,"cik":"0001572000","reported_name":"Lubner David Charles","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-10-06T20:15:14.000Z","date":"2021-10-04","kind":"grant","acquired":true,"shares":17245,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest and become exercisable on the earlier of (a) the one (1)-year anniversary of the Grant Date and (b) the Company's next annual meeting of stockholders, in each case, so long as the Optionee continues to have a Service Relationship with the Company on such date."}],"balance_after":17245,"derivative":{"exercise_price":3.8,"expiration_date":"2031-10-03","underlying":"Common Stock","underlying_shares":17245},"source":{"system":"sec-edgar","filing":"0000899243-21-039453","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1816736/000089924321039453/doc4.xml","form_type":"4"}},{"id":2637816,"issuer":{"id":95793,"kind":"organization","name":"POINT Biopharma Global Inc.","symbol":"PNT"},"owners":[{"id":25356,"kind":"person","name":"Lubner David Charles","position":1,"cik":"0001572000","reported_name":"Lubner David Charles","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-07-08T20:38:55.000Z","date":"2021-07-06","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests 25% on July 6, 2022 with the remaining 75% vesting in three equal annual installments thereafter."}],"balance_after":25000,"derivative":{"exercise_price":8.47,"expiration_date":"2027-07-06","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001104659-21-090262","document":"tm2121760-8_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1572000/000110465921090262/tm2121760-8_4seq1.xml","form_type":"4"}},{"id":2693684,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":25356,"kind":"person","name":"Lubner David Charles","position":1,"cik":"0001572000","reported_name":"Lubner David Charles","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-05-28T00:37:28.000Z","date":"2021-05-26","kind":"grant","acquired":true,"shares":19596,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on May 26, 2021. The shares underlying the option are scheduled to vest in full on the earlier of (i) May 26, 2022 or (ii) the date of the Issuer's 2022 Annual Meeting of Stockholders"}],"balance_after":19596,"derivative":{"exercise_price":19.56,"expiration_date":"2031-05-25","underlying":"Common Stock","underlying_shares":19596},"source":{"system":"sec-edgar","filing":"0000899243-21-020985","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000089924321020985/doc4.xml","form_type":"4"}},{"id":2754532,"issuer":{"id":2273,"kind":"organization","name":"Disc Medicine, Inc.","symbol":"IRON"},"owners":[{"id":25356,"kind":"person","name":"Lubner David Charles","position":1,"cik":"0001572000","reported_name":"Lubner David Charles","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-04-07T20:07:26.000Z","date":"2021-02-05","kind":"grant","acquired":true,"shares":58855,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest and become exercisable over a period of four years from the Vesting Start Date, February 5, 2021 with 25% vesting on the one year anniversary of the Vesting Start Date, and the remainder vesting over a period of 36 months thereafter, provided that as of each such date the Grantee remains in a Service Relationship with the Company."}],"balance_after":58855,"derivative":{"exercise_price":12.66,"expiration_date":"2031-02-04","underlying":"Common Stock","underlying_shares":58855},"source":{"system":"sec-edgar","filing":"0001213900-21-020635","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1816736/000121390021020635/ownership.xml","form_type":"4"}},{"id":2789406,"issuer":{"id":2273,"kind":"organization","name":"Disc Medicine, Inc.","symbol":"IRON"},"owners":[{"id":25356,"kind":"person","name":"Lubner David Charles","position":1,"cik":"0001572000","reported_name":"Lubner David Charles","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-03-15T20:18:43.000Z","date":"2021-03-12","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest and become exercisable in 36 equal monthly installments following the Grant Date, provided that as of each such date the Grantee remains in a business relationship with the Company."}],"balance_after":25000,"derivative":{"exercise_price":17,"expiration_date":"2031-03-11","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001213900-21-015393","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1816736/000121390021015393/ownership.xml","form_type":"4"}},{"id":2872345,"issuer":{"id":4763,"kind":"organization","name":"Vor Biopharma Inc.","symbol":"VOR"},"owners":[{"id":25356,"kind":"person","name":"Lubner David Charles","position":1,"cik":"0001572000","reported_name":"Lubner David Charles","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-02-09T22:13:14.000Z","date":"2021-02-05","kind":"grant","acquired":true,"shares":16900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/36th of the shares underlying the option vest in equal monthly installments commencing on March 5, 2021, provided that the Reporting Person remains continuously engaged by the Issuer on each such vesting date."}],"balance_after":16900,"derivative":{"exercise_price":18,"expiration_date":"2031-02-04","underlying":"Common Stock","underlying_shares":16900},"source":{"system":"sec-edgar","filing":"0001209191-21-008884","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817229/000120919121008884/doc4.xml","form_type":"4"}},{"id":3023947,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":25356,"kind":"person","name":"Lubner David Charles","position":1,"cik":"0001572000","reported_name":"Lubner David Charles","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series B Preferred Stock","published_at":"2020-09-23T23:10:56.000Z","date":"2020-09-21","kind":"exercise","acquired":false,"shares":177872,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On September 21, 2020, the Series B Preferred Stock automatically converted into Common Stock on a 3.3169-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On September 21, 2020, the Series B Preferred Stock automatically converted into Common Stock on a 3.3169-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On September 21, 2020, the Series B Preferred Stock automatically converted into Common Stock on a 3.3169-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":53625},"source":{"system":"sec-edgar","filing":"0000899243-20-026192","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000089924320026192/doc4.xml","form_type":"4"}},{"id":3023946,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":25356,"kind":"person","name":"Lubner David Charles","position":1,"cik":"0001572000","reported_name":"Lubner David Charles","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series B Preferred Stock","published_at":"2020-09-23T23:10:56.000Z","date":"2020-08-07","kind":"purchase","acquired":true,"shares":177872,"price":2.811,"value":499998.192,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"The Series B Preferred Stock was convertible into common stock on a 3.3169-for-one basis into the number of shares of common stock shown in Column 7 without payment of further consideration at the holder's election or upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The Series B Preferred Stock was convertible into common stock on a 3.3169-for-one basis into the number of shares of common stock shown in Column 7 without payment of further consideration at the holder's election or upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The Series B Preferred Stock was convertible into common stock on a 3.3169-for-one basis into the number of shares of common stock shown in Column 7 without payment of further consideration at the holder's election or upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date."}],"balance_after":177872,"derivative":{"underlying":"Common Stock","underlying_shares":53625},"source":{"system":"sec-edgar","filing":"0000899243-20-026192","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000089924320026192/doc4.xml","form_type":"4"}},{"id":3023945,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":25356,"kind":"person","name":"Lubner David Charles","position":1,"cik":"0001572000","reported_name":"Lubner David Charles","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-09-23T23:10:56.000Z","date":"2020-07-31","kind":"grant","acquired":true,"shares":14444,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option was granted on July 31, 2020. The shares underlying the option are scheduled to vest over four years in equal quarterly installments through July 31, 2024, provided that no shares shall vest prior to March 19, 2021."}],"balance_after":14444,"derivative":{"exercise_price":5.54,"expiration_date":"2030-07-30","underlying":"Common Stock","underlying_shares":14444},"source":{"system":"sec-edgar","filing":"0000899243-20-026192","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000089924320026192/doc4.xml","form_type":"4"}},{"id":3023944,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":25356,"kind":"person","name":"Lubner David Charles","position":1,"cik":"0001572000","reported_name":"Lubner David Charles","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-09-23T23:10:56.000Z","date":"2020-07-31","kind":"grant","acquired":true,"shares":11156,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option was granted on July 31, 2020. The shares underlying the option are scheduled to vest over four years in equal quarterly installments through July 31, 2024, provided that no shares shall vest prior to March 19, 2021."}],"balance_after":11156,"derivative":{"exercise_price":5.54,"expiration_date":"2030-07-30","underlying":"Common Stock","underlying_shares":11156},"source":{"system":"sec-edgar","filing":"0000899243-20-026192","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000089924320026192/doc4.xml","form_type":"4"}},{"id":3023943,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":25356,"kind":"person","name":"Lubner David Charles","position":1,"cik":"0001572000","reported_name":"Lubner David Charles","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-09-23T23:10:56.000Z","date":"2020-09-21","kind":"exercise","acquired":true,"shares":53625,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On September 21, 2020, the Series B Preferred Stock automatically converted into Common Stock on a 3.3169-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date."}],"balance_after":53625,"source":{"system":"sec-edgar","filing":"0000899243-20-026192","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000089924320026192/doc4.xml","form_type":"4"}},{"id":3183231,"issuer":{"id":150034,"kind":"organization","name":"Ra Pharmaceuticals, Inc.","symbol":"RARX"},"owners":[{"id":25356,"kind":"person","name":"Lubner David Charles","position":1,"cik":"0001572000","reported_name":"Lubner David Charles","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive VP and CFO"}}],"security":"Restricted Stock Units","published_at":"2020-04-03T09:02:32.000Z","date":"2020-04-02","kind":"disposition_to_issuer","acquired":false,"shares":10416,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Pursuant to the Merger Agreement, at the effective time of the Merger, each restricted stock unit was canceled in exchange for a cash payment equal to $48.00 per share underlying each restricted stock unit."},{"field":"shares","element":"transactionShares","label":"F2","text":"Disposed of pursuant to an Agreement and Plan of Merger (the \"Merger Agreement\"), dated October 9, 2019, among Ra Pharmaceuticals, Inc. (the \"Issuer\"), UCB S.A., and Franq Merger Sub, Inc., providing for the merger (the \"Merger\") of Franq Merger Sub, Inc. into the Issuer, in exchange for a cash payment of $48.00 per share."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, at the effective time of the Merger, each restricted stock unit was canceled in exchange for a cash payment equal to $48.00 per share underlying each restricted stock unit."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, at the effective time of the Merger, each restricted stock unit was canceled in exchange for a cash payment equal to $48.00 per share underlying each restricted stock unit."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the Merger Agreement, at the effective time of the Merger, each restricted stock unit was canceled in exchange for a cash payment equal to $48.00 per share underlying each restricted stock unit."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":10416},"source":{"system":"sec-edgar","filing":"0001104659-20-042772","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1481512/000110465920042772/a4.xml","form_type":"4"}},{"id":3183230,"issuer":{"id":150034,"kind":"organization","name":"Ra Pharmaceuticals, Inc.","symbol":"RARX"},"owners":[{"id":25356,"kind":"person","name":"Lubner David Charles","position":1,"cik":"0001572000","reported_name":"Lubner David Charles","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive VP and CFO"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-04-03T09:02:32.000Z","date":"2020-04-02","kind":"disposition_to_issuer","acquired":false,"shares":133000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Disposed of pursuant to an Agreement and Plan of Merger (the \"Merger Agreement\"), dated October 9, 2019, among Ra Pharmaceuticals, Inc. (the \"Issuer\"), UCB S.A., and Franq Merger Sub, Inc., providing for the merger (the \"Merger\") of Franq Merger Sub, Inc. into the Issuer, in exchange for a cash payment of $48.00 per share."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, at the effective time of the Merger, each option, whether vested or unvested, was cancelled in exchange for a cash payment equal to: (a) the number of shares of Issuer common stock underlying the option, multiplied by (b) the excess of $48.00 over the per share exercise price of such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, at the effective time of the Merger, each option, whether vested or unvested, was cancelled in exchange for a cash payment equal to: (a) the number of shares of Issuer common stock underlying the option, multiplied by (b) the excess of $48.00 over the per share exercise price of such option."}],"balance_after":0,"derivative":{"exercise_price":21,"expiration_date":"2029-02-01","underlying":"Common Stock","underlying_shares":133000},"source":{"system":"sec-edgar","filing":"0001104659-20-042772","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1481512/000110465920042772/a4.xml","form_type":"4"}},{"id":3183229,"issuer":{"id":150034,"kind":"organization","name":"Ra Pharmaceuticals, Inc.","symbol":"RARX"},"owners":[{"id":25356,"kind":"person","name":"Lubner David Charles","position":1,"cik":"0001572000","reported_name":"Lubner David Charles","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive VP and CFO"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-04-03T09:02:32.000Z","date":"2020-04-02","kind":"disposition_to_issuer","acquired":false,"shares":62500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Disposed of pursuant to an Agreement and Plan of Merger (the \"Merger Agreement\"), dated October 9, 2019, among Ra Pharmaceuticals, Inc. (the \"Issuer\"), UCB S.A., and Franq Merger Sub, Inc., providing for the merger (the \"Merger\") of Franq Merger Sub, Inc. into the Issuer, in exchange for a cash payment of $48.00 per share."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, at the effective time of the Merger, each option, whether vested or unvested, was cancelled in exchange for a cash payment equal to: (a) the number of shares of Issuer common stock underlying the option, multiplied by (b) the excess of $48.00 over the per share exercise price of such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, at the effective time of the Merger, each option, whether vested or unvested, was cancelled in exchange for a cash payment equal to: (a) the number of shares of Issuer common stock underlying the option, multiplied by (b) the excess of $48.00 over the per share exercise price of such option."}],"balance_after":0,"derivative":{"exercise_price":7.33,"expiration_date":"2028-02-01","underlying":"Common Stock","underlying_shares":65000},"source":{"system":"sec-edgar","filing":"0001104659-20-042772","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1481512/000110465920042772/a4.xml","form_type":"4"}},{"id":3183228,"issuer":{"id":150034,"kind":"organization","name":"Ra Pharmaceuticals, Inc.","symbol":"RARX"},"owners":[{"id":25356,"kind":"person","name":"Lubner David Charles","position":1,"cik":"0001572000","reported_name":"Lubner David Charles","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive VP and CFO"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-04-03T09:02:32.000Z","date":"2020-04-02","kind":"disposition_to_issuer","acquired":false,"shares":112500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Disposed of pursuant to an Agreement and Plan of Merger (the \"Merger Agreement\"), dated October 9, 2019, among Ra Pharmaceuticals, Inc. (the \"Issuer\"), UCB S.A., and Franq Merger Sub, Inc., providing for the merger (the \"Merger\") of Franq Merger Sub, Inc. into the Issuer, in exchange for a cash payment of $48.00 per share."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, at the effective time of the Merger, each option, whether vested or unvested, was cancelled in exchange for a cash payment equal to: (a) the number of shares of Issuer common stock underlying the option, multiplied by (b) the excess of $48.00 over the per share exercise price of such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, at the effective time of the Merger, each option, whether vested or unvested, was cancelled in exchange for a cash payment equal to: (a) the number of shares of Issuer common stock underlying the option, multiplied by (b) the excess of $48.00 over the per share exercise price of such option."}],"balance_after":0,"derivative":{"exercise_price":16.64,"expiration_date":"2027-02-01","underlying":"Common Stock","underlying_shares":112500},"source":{"system":"sec-edgar","filing":"0001104659-20-042772","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1481512/000110465920042772/a4.xml","form_type":"4"}},{"id":3183227,"issuer":{"id":150034,"kind":"organization","name":"Ra Pharmaceuticals, Inc.","symbol":"RARX"},"owners":[{"id":25356,"kind":"person","name":"Lubner David Charles","position":1,"cik":"0001572000","reported_name":"Lubner David Charles","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive VP and CFO"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-04-03T09:02:32.000Z","date":"2020-04-02","kind":"disposition_to_issuer","acquired":false,"shares":28571,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Disposed of pursuant to an Agreement and Plan of Merger (the \"Merger Agreement\"), dated October 9, 2019, among Ra Pharmaceuticals, Inc. (the \"Issuer\"), UCB S.A., and Franq Merger Sub, Inc., providing for the merger (the \"Merger\") of Franq Merger Sub, Inc. into the Issuer, in exchange for a cash payment of $48.00 per share."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, at the effective time of the Merger, each option, whether vested or unvested, was cancelled in exchange for a cash payment equal to: (a) the number of shares of Issuer common stock underlying the option, multiplied by (b) the excess of $48.00 over the per share exercise price of such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, at the effective time of the Merger, each option, whether vested or unvested, was cancelled in exchange for a cash payment equal to: (a) the number of shares of Issuer common stock underlying the option, multiplied by (b) the excess of $48.00 over the per share exercise price of such option."}],"balance_after":0,"derivative":{"exercise_price":5.6,"expiration_date":"2026-08-16","underlying":"Common Stock","underlying_shares":28571},"source":{"system":"sec-edgar","filing":"0001104659-20-042772","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1481512/000110465920042772/a4.xml","form_type":"4"}},{"id":3183226,"issuer":{"id":150034,"kind":"organization","name":"Ra Pharmaceuticals, Inc.","symbol":"RARX"},"owners":[{"id":25356,"kind":"person","name":"Lubner David Charles","position":1,"cik":"0001572000","reported_name":"Lubner David Charles","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive VP and CFO"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-04-03T09:02:32.000Z","date":"2020-04-02","kind":"disposition_to_issuer","acquired":false,"shares":92283,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Disposed of pursuant to an Agreement and Plan of Merger (the \"Merger Agreement\"), dated October 9, 2019, among Ra Pharmaceuticals, Inc. (the \"Issuer\"), UCB S.A., and Franq Merger Sub, Inc., providing for the merger (the \"Merger\") of Franq Merger Sub, Inc. into the Issuer, in exchange for a cash payment of $48.00 per share."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, at the effective time of the Merger, each option, whether vested or unvested, was cancelled in exchange for a cash payment equal to: (a) the number of shares of Issuer common stock underlying the option, multiplied by (b) the excess of $48.00 over the per share exercise price of such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, at the effective time of the Merger, each option, whether vested or unvested, was cancelled in exchange for a cash payment equal to: (a) the number of shares of Issuer common stock underlying the option, multiplied by (b) the excess of $48.00 over the per share exercise price of such option."}],"balance_after":0,"derivative":{"exercise_price":2.87,"expiration_date":"2026-03-01","underlying":"Common Stock","underlying_shares":92283},"source":{"system":"sec-edgar","filing":"0001104659-20-042772","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1481512/000110465920042772/a4.xml","form_type":"4"}},{"id":3183225,"issuer":{"id":150034,"kind":"organization","name":"Ra Pharmaceuticals, Inc.","symbol":"RARX"},"owners":[{"id":25356,"kind":"person","name":"Lubner David Charles","position":1,"cik":"0001572000","reported_name":"Lubner David Charles","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive VP and CFO"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-04-03T09:02:32.000Z","date":"2020-04-02","kind":"disposition_to_issuer","acquired":false,"shares":115572,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Disposed of pursuant to an Agreement and Plan of Merger (the \"Merger Agreement\"), dated October 9, 2019, among Ra Pharmaceuticals, Inc. (the \"Issuer\"), UCB S.A., and Franq Merger Sub, Inc., providing for the merger (the \"Merger\") of Franq Merger Sub, Inc. into the Issuer, in exchange for a cash payment of $48.00 per share."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, at the effective time of the Merger, each option, whether vested or unvested, was cancelled in exchange for a cash payment equal to: (a) the number of shares of Issuer common stock underlying the option, multiplied by (b) the excess of $48.00 over the per share exercise price of such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, at the effective time of the Merger, each option, whether vested or unvested, was cancelled in exchange for a cash payment equal to: (a) the number of shares of Issuer common stock underlying the option, multiplied by (b) the excess of $48.00 over the per share exercise price of such option."}],"balance_after":0,"derivative":{"exercise_price":2.87,"expiration_date":"2026-03-01","underlying":"Common Stock","underlying_shares":115572},"source":{"system":"sec-edgar","filing":"0001104659-20-042772","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1481512/000110465920042772/a4.xml","form_type":"4"}},{"id":3183224,"issuer":{"id":150034,"kind":"organization","name":"Ra Pharmaceuticals, Inc.","symbol":"RARX"},"owners":[{"id":25356,"kind":"person","name":"Lubner David Charles","position":1,"cik":"0001572000","reported_name":"Lubner David Charles","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive VP and CFO"}}],"security":"Common Stock","published_at":"2020-04-03T09:02:32.000Z","date":"2020-04-02","kind":"disposition_to_issuer","acquired":false,"shares":15622,"price":48,"value":749856.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Includes (i) 377 shares of Issuer common stock acquired under the Issuer's Employee Stock Purchase Plan on December 10, 2019 and (ii) 7,248 shares of Issuer common stock acquired upon the vesting and net settlement of restricted stock units on February 1, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Disposed of pursuant to an Agreement and Plan of Merger (the \"Merger Agreement\"), dated October 9, 2019, among Ra Pharmaceuticals, Inc. (the \"Issuer\"), UCB S.A., and Franq Merger Sub, Inc., providing for the merger (the \"Merger\") of Franq Merger Sub, Inc. into the Issuer, in exchange for a cash payment of $48.00 per share."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-20-042772","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1481512/000110465920042772/a4.xml","form_type":"4"}},{"id":3496671,"issuer":{"id":156809,"kind":"organization","name":"Nightstar Therapeutics plc","symbol":"NITE"},"owners":[{"id":25356,"kind":"person","name":"Lubner David Charles","position":1,"cik":"0001572000","reported_name":"Lubner David Charles","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-06-07T20:36:33.000Z","date":"2019-06-07","kind":"disposition_to_issuer","acquired":false,"shares":21000,"price":11.93,"value":250530.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the payment per share received in exchange for the cancellation of each option of $25.50, less the applicable exercise price."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"In connection with the acquisition by Tungsten Bidco Limited of the entire issued and to be issued share capital of the Issuer on June 7, 2019 by means of a scheme of arrangement under Part 26 of the UK Companies Act 2006, all stock options were cancelled in exchange for a payment equal to $25.50 with respect to each ordinary share subject to the option award, less the applicable exercise price."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The ordinary shares, nominal value GBP 0.01 per share, of Nightstar Therapeutics plc (the \"Issuer\") may be represented by American Depositary Shares (\"ADSs\"). Each ADS represents one ordinary share of the Issuer."}],"balance_after":0,"derivative":{"exercise_price":13.57,"expiration_date":"2029-01-24","underlying":"Ordinary Shares","underlying_shares":21000},"source":{"system":"sec-edgar","filing":"0001209191-19-035563","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1572000/000120919119035563/doc4.xml","form_type":"4"}},{"id":3496670,"issuer":{"id":156809,"kind":"organization","name":"Nightstar Therapeutics plc","symbol":"NITE"},"owners":[{"id":25356,"kind":"person","name":"Lubner David Charles","position":1,"cik":"0001572000","reported_name":"Lubner David Charles","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-06-07T20:36:33.000Z","date":"2019-06-07","kind":"disposition_to_issuer","acquired":false,"shares":18200,"price":13.23,"value":240786.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the payment per share received in exchange for the cancellation of each option of $25.50, less the applicable exercise price."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"In connection with the acquisition by Tungsten Bidco Limited of the entire issued and to be issued share capital of the Issuer on June 7, 2019 by means of a scheme of arrangement under Part 26 of the UK Companies Act 2006, all stock options were cancelled in exchange for a payment equal to $25.50 with respect to each ordinary share subject to the option award, less the applicable exercise price."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The ordinary shares, nominal value GBP 0.01 per share, of Nightstar Therapeutics plc (the \"Issuer\") may be represented by American Depositary Shares (\"ADSs\"). Each ADS represents one ordinary share of the Issuer."}],"balance_after":0,"derivative":{"exercise_price":12.27,"expiration_date":"2028-02-27","underlying":"Ordinary Shares","underlying_shares":18200},"source":{"system":"sec-edgar","filing":"0001209191-19-035563","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1572000/000120919119035563/doc4.xml","form_type":"4"}},{"id":3496669,"issuer":{"id":156809,"kind":"organization","name":"Nightstar Therapeutics plc","symbol":"NITE"},"owners":[{"id":25356,"kind":"person","name":"Lubner David Charles","position":1,"cik":"0001572000","reported_name":"Lubner David Charles","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2019-06-07T20:36:33.000Z","date":"2019-06-07","kind":"disposition_to_issuer","acquired":false,"shares":29124,"price":25.5,"value":742662.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The ordinary shares, nominal value GBP 0.01 per share, of Nightstar Therapeutics plc (the \"Issuer\") may be represented by American Depositary Shares (\"ADSs\"). Each ADS represents one ordinary share of the Issuer."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-19-035563","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1572000/000120919119035563/doc4.xml","form_type":"4"}},{"id":3674280,"issuer":{"id":150034,"kind":"organization","name":"Ra Pharmaceuticals, Inc.","symbol":"RARX"},"owners":[{"id":25356,"kind":"person","name":"Lubner David Charles","position":1,"cik":"0001572000","reported_name":"Lubner David Charles","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive V.P. & CFO"}}],"security":"Restricted Stock Units","published_at":"2019-02-05T19:39:45.000Z","date":"2019-02-01","kind":"exercise","acquired":false,"shares":10417,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On February 1, 2018, the reporting person was granted 31,250 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Not applicable."}],"balance_after":20833,"derivative":{"underlying":"Common Stock","underlying_shares":10417},"source":{"system":"sec-edgar","filing":"0001104659-19-005907","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1481512/000110465919005907/a4.xml","form_type":"4"}},{"id":3674279,"issuer":{"id":150034,"kind":"organization","name":"Ra Pharmaceuticals, Inc.","symbol":"RARX"},"owners":[{"id":25356,"kind":"person","name":"Lubner David Charles","position":1,"cik":"0001572000","reported_name":"Lubner David Charles","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive V.P. & CFO"}}],"security":"Options to Purchase Common Stock","published_at":"2019-02-05T19:39:45.000Z","date":"2019-02-01","kind":"grant","acquired":true,"shares":133000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These stock options vest in 48 equal monthly installments on each monthly anniversary following February 1, 2019, the grant date."}],"balance_after":133000,"derivative":{"exercise_price":21,"expiration_date":"2029-02-01","underlying":"Common Stock","underlying_shares":133000},"source":{"system":"sec-edgar","filing":"0001104659-19-005907","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1481512/000110465919005907/a4.xml","form_type":"4"}},{"id":3674278,"issuer":{"id":150034,"kind":"organization","name":"Ra Pharmaceuticals, Inc.","symbol":"RARX"},"owners":[{"id":25356,"kind":"person","name":"Lubner David Charles","position":1,"cik":"0001572000","reported_name":"Lubner David Charles","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive V.P. & CFO"}}],"security":"COMMON STOCK","published_at":"2019-02-05T19:39:45.000Z","date":"2019-02-01","kind":"tax_withholding","acquired":false,"shares":3291,"price":21,"value":69111.0,"ownership":{"direct":true},"balance_after":7126,"source":{"system":"sec-edgar","filing":"0001104659-19-005907","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1481512/000110465919005907/a4.xml","form_type":"4"}},{"id":3674277,"issuer":{"id":150034,"kind":"organization","name":"Ra Pharmaceuticals, Inc.","symbol":"RARX"},"owners":[{"id":25356,"kind":"person","name":"Lubner David Charles","position":1,"cik":"0001572000","reported_name":"Lubner David Charles","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive V.P. & CFO"}}],"security":"COMMON STOCK","published_at":"2019-02-05T19:39:45.000Z","date":"2019-02-01","kind":"exercise","acquired":true,"shares":10417,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."}],"balance_after":10417,"source":{"system":"sec-edgar","filing":"0001104659-19-005907","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1481512/000110465919005907/a4.xml","form_type":"4"}},{"id":3683440,"issuer":{"id":156809,"kind":"organization","name":"Nightstar Therapeutics plc","symbol":"NITE"},"owners":[{"id":25356,"kind":"person","name":"Lubner David Charles","position":1,"cik":"0001572000","reported_name":"Lubner David Charles","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-01-30T02:03:57.000Z","date":"2019-01-25","kind":"grant","acquired":true,"shares":21000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests in full on the close of business the day before the 2020 Annual General Meeting of Shareholders."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"The ordinary shares, nominal value GBP 0.01 per share, of the Issuer may be represented by American Depositary Shares (\"ADSs\"). Each ADS represents one ordinary share of the Issuer."}],"balance_after":21000,"derivative":{"exercise_price":13.57,"expiration_date":"2029-01-24","underlying":"Ordinary Shares","underlying_shares":21000},"source":{"system":"sec-edgar","filing":"0001209191-19-005963","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1572000/000120919119005963/doc4.xml","form_type":"4"}},{"id":4076293,"issuer":{"id":150034,"kind":"organization","name":"Ra Pharmaceuticals, Inc.","symbol":"RARX"},"owners":[{"id":25356,"kind":"person","name":"Lubner David Charles","position":1,"cik":"0001572000","reported_name":"Lubner David Charles","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive V.P. & CFO"}}],"security":"Restricted Stock Units","published_at":"2018-02-05T21:46:14.000Z","date":"2018-02-01","kind":"grant","acquired":true,"shares":31250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These Restricted Stock Units vest in three equal installments on each of February 1, 2019, February 1, 2020, and February 1, 2021."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Not applicable."}],"balance_after":31250,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":31250},"source":{"system":"sec-edgar","filing":"0001104659-18-006634","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1481512/000110465918006634/a4.xml","form_type":"4"}},{"id":4076292,"issuer":{"id":150034,"kind":"organization","name":"Ra Pharmaceuticals, Inc.","symbol":"RARX"},"owners":[{"id":25356,"kind":"person","name":"Lubner David Charles","position":1,"cik":"0001572000","reported_name":"Lubner David Charles","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive V.P. & CFO"}}],"security":"Options to Purchase Common Stock","published_at":"2018-02-05T21:46:14.000Z","date":"2018-02-01","kind":"grant","acquired":true,"shares":62500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These stock options vest in 48 equal monthly installments on each monthly anniversary thereafter following February 1, 2018, the grant date."}],"balance_after":62500,"derivative":{"exercise_price":7.33,"expiration_date":"2028-02-01","underlying":"Common Stock","underlying_shares":62500},"source":{"system":"sec-edgar","filing":"0001104659-18-006634","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1481512/000110465918006634/a4.xml","form_type":"4"}},{"id":4468656,"issuer":{"id":150034,"kind":"organization","name":"Ra Pharmaceuticals, Inc.","symbol":"RARX"},"owners":[{"id":25356,"kind":"person","name":"Lubner David Charles","position":1,"cik":"0001572000","reported_name":"Lubner David Charles","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive V.P. & CFO"}}],"security":"Options to Purchase Common Stock","published_at":"2017-02-03T16:26:32.000Z","date":"2017-02-01","kind":"grant","acquired":true,"shares":112500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These stock options vest in 48 equal monthly installments at the end of each month following February 1, 2017, the grant date."}],"balance_after":112500,"derivative":{"exercise_price":16.64,"expiration_date":"2027-02-01","underlying":"Common Stock","underlying_shares":112500},"source":{"system":"sec-edgar","filing":"0001104659-17-006439","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1481512/000110465917006439/a4.xml","form_type":"4"}},{"id":4571884,"issuer":{"id":150034,"kind":"organization","name":"Ra Pharmaceuticals, Inc.","symbol":"RARX"},"owners":[{"id":25356,"kind":"person","name":"Lubner David Charles","position":1,"cik":"0001572000","reported_name":"Lubner David Charles","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & CFO"}}],"security":"Options to Purchase Common Stock","published_at":"2016-10-31T16:52:43.000Z","date":"2016-10-31","kind":"grant","acquired":true,"shares":29285,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These stock options vest in 48 equal monthly installments at the end of each month following October 31, 2016, which was the date of the consummation of the initial public offering of the Issuer."}],"balance_after":29285,"derivative":{"exercise_price":2.87,"expiration_date":"2026-03-01","underlying":"Common Stock","underlying_shares":29285},"source":{"system":"sec-edgar","filing":"0001104659-16-153350","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1481512/000110465916153350/a4.xml","form_type":"4"}}]}